These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15613062)

  • 21. Moxonidine well tolerated and effective in the treatment of viscerally obese, non-controlled hypertensive patients.
    Cardiovasc J S Afr; 2006; 17(4):209. PubMed ID: 17001427
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
    Kaaja R; Kujala S; Manhem K; Katzman P; Kibarskis A; Antikainen R; Ylihärsilä H; Erkkola R; Tuomilehto J
    Int J Clin Pharmacol Ther; 2007 Jul; 45(7):394-401. PubMed ID: 17725246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a Modest Weight Loss in Normalizing Blood Pressure in Obese Subjects on Antihypertensive Drugs.
    Gilardini L; Redaelli G; Croci M; Conti A; Pasqualinotto L; Invitti C
    Obes Facts; 2016; 9(4):251-8. PubMed ID: 27454447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension].
    Baliakina EV; Patrusheva IF; Rynskova EE; Iurenev AP
    Ter Arkh; 1998; 70(1):15-9. PubMed ID: 9532644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
    De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
    Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
    Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
    Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with moxonidine.
    Prichard BN
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():49-58. PubMed ID: 8068579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
    Sharma AM; Bakris G; Neutel JM; Littlejohn TW; Kobe M; Ting N; Ley L
    Clin Ther; 2012 Mar; 34(3):537-51. PubMed ID: 22386829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
    Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
    Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
    Hsueh WA; Shojaee A; Maa JF; Neutel JM
    Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxonidine treatment of hypertensive patients with advanced renal failure.
    Vonend O; Marsalek P; Russ H; Wulkow R; Oberhauser V; Rump LC
    J Hypertens; 2003 Sep; 21(9):1709-17. PubMed ID: 12923404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.
    Chrisp P; Faulds D
    Drugs; 1992 Dec; 44(6):993-1012. PubMed ID: 1282869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraindividual comparison of moxonidine and prazosin in hypertensive patients.
    Plänitz V
    Eur J Clin Pharmacol; 1986; 29(6):645-50. PubMed ID: 3709608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.